Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Translational Medicine Summit

Huiqing Wu's Biography



Huiqing Wu, Assistant Professor, City of Hope National Medical Center and Beckman Research Institute

Huiqing Wu graduated from Shanghai Medical University School of Medicine, Shanghai, China in 1987 (M.D.) and had his M.S. (Master of Science) in Cellular and Molecular Biology from University of Kentucky, Lexington, KY in 1992.  He finished his residency training in Pathology at The Mount Sinai School of Medicine, New York, NY in 2002 and then did his Hematopathology, Surgical Pathology and Research (translational research in prostate cancer) Fellowship at Brigham and Women's Hospital, Harvard Medical School, Boston, MA from 2002 to 2006.  He has been Staff Pathologist and Assistant Professor at City of Hope National Medical Center and Beckman Research Institute, Duarte, CA since 2006.  His research areas include (1) Characterization of small non-coding RNA expression in metastatic renal cell carcinoma and hormonal resistant prostate cancer; (2) MicroRNA signature for clear cell renal cell carcinoma metastasis and prognosis; (3) MicroRNA signature for prostate cancer metastasis and recurrence.  The accomplishments of his laboratory include (A) Being the first to successfully use FFPE tissue cohort samples for whole genome small RNA deep sequencing; (B) Building a 4-miRNA signature to predict clear cell renal cell carcinoma metastasis and prognosis (US patent pending); (C) Revealing a group of small RNAs derived from rRNAs, tRNAs and other non-coding RNAs to be involved in renal cell carcinoma metastasis and progression. 

Huiqing Wu Image

MicroRNA Signature for the Prediction of Renal Cell Carcinoma Metastasis and Prognosis

Friday, 7 June 2013 at 14:00

Add to Calendar ▼2013-06-07 14:00:002013-06-07 15:00:00Europe/LondonMicroRNA Signature for the Prediction of Renal Cell Carcinoma Metastasis and Prognosis Translational Medicine Summit in HamburgHamburgSELECTBIOenquiries@selectbiosciences.com

This study is to develop and validate a microRNA expression signature for the early prediction of clear cell renal cell carcinoma metastasis and prognosis.


Add to Calendar ▼2013-06-06 00:00:002013-06-07 00:00:00Europe/LondonTranslational Medicine SummitTranslational Medicine Summit in HamburgHamburgSELECTBIOenquiries@selectbiosciences.com